Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:3112-3118
Published online before print June 6, 2005, doi: 10.1161/CIRCULATIONAHA.104.497107
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
111/23/3112    most recent
CIRCULATIONAHA.104.497107v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gupta, H.
Right arrow Articles by Anantharamaiah, G.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gupta, H.
Right arrow Articles by Anantharamaiah, G.M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
Related Collections
Right arrow Animal models of human disease
Right arrow Lipid and lipoprotein metabolism
Right arrow Endothelium/vascular type/nitric oxide
Right arrowRelated Article

(Circulation. 2005;111:3112-3118.)
© 2005 American Heart Association, Inc.


Vascular Medicine

Apolipoprotein E Mimetic Peptide Dramatically Lowers Plasma Cholesterol and Restores Endothelial Function in Watanabe Heritable Hyperlipidemic Rabbits

Himanshu Gupta, MD; C. Roger White, PhD; Shaila Handattu, PhD; David W. Garber, PhD; Geeta Datta, PhD; Manjula Chaddha, PhD; Lijun Dai, PhD; Sandra H. Gianturco, PhD; William A. Bradley, PhD; G.M. Anantharamaiah, PhD

From the Departments of Medicine, Biochemistry, and Molecular Genetics and the Atherosclerosis Research Unit, University of Alabama at Birmingham.

Correspondence to G.M. Anantharamaiah, PhD, 1808 7th Ave S, DH-668, UAB Medical Center, Birmingham, AL 35294. E-mail ananth{at}uab.edu

Received August 2, 2004; revision received December 3, 2004; accepted February 24, 2005.

Background— These studies were designed to determine whether the dual-domain peptide with a class A amphipathic helix linked to the receptor-binding domain of apolipoprotein (apo) E (Ac-hE-18A-NH2) possesses both antidyslipidemic and antiinflammatory properties.

Methods and Results— A single bolus (15 mg/kg IV) of Ac-hE-18A-NH2 that contains LRKLRKRLLR (141- to 150-residue region of apo E) covalently linked to apo A-I mimetic peptide 18A not only reduced plasma cholesterol levels (baseline, 562±29.0 mg/dL versus 287.7±22.0 mg/dL at 18 hours, P<0.001) in the Watanabe heritable hyperlipidemic rabbit model but also significantly improved arterial endothelial function. This improvement was associated with a reduction in 2 markers of oxidative stress. First, the plasma lipid hydroperoxide content was reduced significantly, an effect associated with a 5-fold increase in HDL paraoxonase activity. Second, the formation of superoxide anion, a scavenger of nitric oxide, was also significantly reduced in arteries of these animals.

Conclusions— Because dyslipidemia and endothelial dysfunction are common features of the atherosclerotic disease process, this unique dual-domain peptide has ideal composite properties that ameliorate key contributory factors to atherosclerosis.


Key Words: lipoproteins • endothelium • metabolism • nitric oxide • arteriosclerosis


Related Article:

Issue Highlights
Circulation 2005 111: 3015. [Extract] [Full Text]



This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
A. Kontush and M. J. Chapman
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374.
[Abstract] [Full Text] [PDF]